乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

SGO

<乌鸦传媒>Intraperitoneal Carboplatin Boosts PFS in Ovarian Cancer

Should the gynecologic oncology community reconsider IP therapy?

<乌鸦传媒>It's Official: Minimally Invasive Hysterectomy Not Safer in Cervical Cancer

Final analysis of LACC trial confirms earlier findings

<乌鸦传媒>Lenvatinib Packaging for Endometrial Cancer Tied to $168 Million in Overspending

Presenter breaks news at SGO that drug developer commits to overhauling dose reduction program

<乌鸦传媒>Selinexor Proves Mettle in Advanced or Recurrent Endometrial Cancer

Benefit was greatest among patients with wild-type p53 cancer in SIENDO trial

<乌鸦传媒>Novel ADC Promising in Tough-to-Treat Ovarian Cancer

Ocular AEs an issue with mirvetuximab in folate receptor alpha-high platinum-resistant disease

<乌鸦传媒>Add-on Pembrolizumab Tied to Good QoL in Women With Advanced Cervical Cancer

PRO-based analysis of KEYNOTE-826 trial shows favorable benefit-risk ratio

<乌鸦传媒>Adjuvant Chemo Disappoints in Low-Grade Serous Ovarian Cancer

Study suggests no improvement in overall survival

<乌鸦传媒>Triage System Gets High Marks for Ovarian Cancer Debulking Surgery

Key factors predicted threefold higher risk of 90-day mortality with primary surgery

<乌鸦传媒>HIPEC Combo Doubles PFS in Advanced Ovarian Cancer

Cisplatin/paclitaxel boosts outcomes without increasing complications in registry study

<乌鸦传媒>Combo Tx Active in Recurrent, Platinum-Resistant Ovarian Cancer

Ixabepilone plus bevacizumab yielded responses in a third of patients

<乌鸦传媒>Little Benefit With Adjuvant Therapy for High-Risk Endometrial Cancer

Chemo prevented relapse but did not improve survival, no benefit from radiotherapy

<乌鸦传媒>Androgen Receptor Inhibitor Active in Endometrial Cancer

SGO: Apatinib for platinum-resistant ovarian cancer, pembrolizumab for advanced vulvar cancer

<乌鸦传媒>Hormonal IUD Shows Promise in Early Endometrial Cancer

Regression seen in 82% of women with precancerous lesions

<乌鸦传媒>Small Molecule Inhibitor Shows Promise in Resistant Ovarian Cancer

Responses in 37% of patients with AVB-500, higher without prior bevacizumab

<乌鸦传媒>Is MIS Viable for Interval Debulking in Ovarian Cancer?

Retrospective study compared approach versus open surgery after neoadjuvant chemotherapy

<乌鸦传媒>PARP Inhibitor Tops Chemo for Recurrent BRCA Ovarian Cancer

Modest improvement in PFS with rucaparib but worse outcome for reversion mutation

<乌鸦传媒>Practice-Changing Trial in Second-Line Endometrial Cancer

Pembrolizumab plus lenvatinib improved median OS by nearly 7 months versus chemotherapy

<乌鸦传媒>Avelumab Flops Again in Ovarian Cancer

Another negative phase III trial, now in the first-line setting

<乌鸦传媒>PARP Inhibitors Still Work in HRD-Low Ovarian Cancer

In VELIA, homologous recombination deficiency score prognostic but not predictive

<乌鸦传媒>KRAS May Predict Benefit of MEK Inhibitors in Some Ovarian Cancers

Nearly 7-month PFS boost in patients with KRAS mutations

<乌鸦传媒>Add-On Metformin No Help in Advanced Endometrial Cancer

Trial highlights deep racial disparities in treatment response, survival outcomes

<乌鸦传媒>Herceptin Boosts OS in HER2-Positive Uterine Cancer

New data bolster targeted approach for aggressive tumor type

<乌鸦传媒>Post-Op HPV Vaccine Cuts Cervical Precancer Recurrences

Plus osteoporosis in gynecologic cancer survivors, and a novel approach to CIN2/3

<乌鸦传媒>Potential Game Changer for Endometrial Cancer

A 30% response rate in recurrent/advanced disease, 49% in MSI-H tumors

<乌鸦传媒>Early Data Send Strong Signal in Advanced Gyn Cancers

Clinical benefit rate tops 90% in pair of single-center studies

<乌鸦传媒>'End of the Road' for Trabectedin in Ovarian Cancer?

Trial stopped for futility, but 13-month OS improvement seen in patients with BRCA mutations

<乌鸦传媒>When PARP Inhibitors Fail in Ovarian Cancer

Study identifies subgroup for whom another go could be worthwhile

<乌鸦传媒>Avelumab Combo Falls Short in Advanced Ovarian Ca

But showed promise in PD-L1-positive group

<乌鸦传媒>PARP Inhibitor Benefit Gets a TWiST in Recurrent Ovarian Ca

Analysis attempts to quantify patients' quality of survival

<乌鸦传媒>Studies Seek Role for Anti-PD-1 Drugs in Gyn Cancers

Activity in resistant ovarian, mutated endometrial cancers

<乌鸦传媒>Unexpected Outcome in Hysterectomy Study

More cancer recurrences, worse survival with minimally invasive surgery

<乌鸦传媒>Women Do Well Without Opioids after Gyn Surgery

An 89% drop in opioid use with restrictive prescribing protocol

<乌鸦传媒>Gyn Cancer Research Gets Short Shrift in Funding

Mortality-adjusted analysis shows huge disparity versus other cancers

<乌鸦传媒>HPV-Targeted Drug Sets Survival Mark in Cervical Cancer

Highest-ever 12-month survival in recurrent, metastatic disease

<乌鸦传媒>Survival Bump in IVB Cervical Cancer with Pelvic RT

Improved OS, PFS in retrospective analysis

<乌鸦传媒>Anti-PARP Tx Works in Advanced Ovarian Cancer

TAMPA, Fla. -- Advanced ovarian cancer treated with PARP inhibitor maintenance therapy had significant improvement in progression-free survival, extending beyond first progression, investigators reported.

<乌鸦传媒>Cancer Ascites Responds to Outpatient Tx

TAMPA, Fla. -- Outpatient treatment of malignant ascites with a monoclonal antibody proved safe and feasible and led to a survival benefit in gynecologic cancer patients who could receive chemotherapy, a small clinical study showed.

<乌鸦传媒>Extreme Obesity Adds More Risk in Hysterectomy

AUSTIN, Texas -- Increasingly severe obesity drives up complication rates after hysterectomy, and outcomes continually worsen with rising body mass index, according to results from a study reported here.

<乌鸦传媒>SGO: Low Cancer Risk with Septated Ovarian Tumors

SAN FRANCISCO -- Septated ovarian tumors have a low risk of malignancy and can be followed safely with ultrasound, data from a large prospective cohort study showed.